Related Experiment Video
Updated: Jun 15, 2026

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats
David Pascual1, Carlos Goicoechea, Elisa Burgos
1Departamento de Farmacología y Nutrición, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avda. Atenas s/n, Alcorcón, Madrid, 28922, Spain. david.pascual@urjc.es
Abstract:
Nowadays, there are no validated drugs to control the neuropathic pain induced by paclitaxel, one of the most effective antineoplastic drugs. The aim was to study the involvement of opioid and NMDA receptor on established paclitaxel-induced pain, testing three common analgesics drugs morphine, ketamine and methadone. Animals received four intraperitoneal (i.p.) injections on alternate days of paclitaxel (1mg/kg). Three weeks later, animals showed a mechanical and heat allodynia/hyperalgesia. Morphine (1, 2.5, 5 and 10mg/kg) abolished the reduction in the mechanical and thermal withdrawal thresholds in a dose dependent manner. This effect was blocked by naloxone. Only highest dose of ketamine (50mg/kg) was able to increase the mechanical and thermal threshold and returned to basal values. Subanalgesic doses of morphine (1mg/kg) and ketamine (12.5mg/kg) produced an additive effect on heat hyperalgesia reaching an antinociceptive effect. This combination did not induce any change on tactile allodynia. Methadone (2.5 and 5mg/kg) produced an analgesic effect that was completely antagonized by naloxone in both tests. Our results confirm that: the activation of opioids receptor produced analgesia; the blockade of NMDA receptors produce antinociception but at high doses with motor impairments and low doses of ketamine enhancing the effect of opioids.
Insights
Paclitaxel-induced neuropathic pain can be managed by targeting opioid and NMDA receptors. Morphine and methadone activate opioid receptors, while ketamine blocks NMDA receptors, offering pain relief.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Paclitaxel is a widely used chemotherapy drug.
- Neuropathic pain is a common and debilitating side effect of paclitaxel treatment.
- Currently, no validated drugs effectively manage paclitaxel-induced neuropathic pain.
Purpose of the Study:
- To investigate the role of opioid and NMDA receptors in paclitaxel-induced neuropathic pain.
- To evaluate the efficacy of morphine, ketamine, and methadone in managing this pain model.
Main Methods:
- Paclitaxel was administered intraperitoneally to animals on alternate days.
- Neuropathic pain was assessed by mechanical and thermal withdrawal thresholds.
- The effects of morphine, ketamine, and methadone, alone and in combination, were evaluated.
- The involvement of opioid receptors was confirmed using naloxone.
Main Results:
- Morphine and methadone demonstrated dose-dependent analgesic effects, blocked by naloxone, confirming opioid receptor involvement.
- Ketamine showed antinociceptive effects at a high dose (50mg/kg) but caused motor impairment.
- Subanalgesic doses of morphine and ketamine had an additive effect on heat hyperalgesia, but not tactile allodynia.
Conclusions:
- Opioid receptor activation effectively produces analgesia in paclitaxel-induced neuropathic pain.
- NMDA receptor blockade with ketamine provides antinociception, particularly at higher doses, though motor impairments are a concern.
- Low-dose ketamine can enhance the analgesic effects of opioids, suggesting a synergistic therapeutic potential.
Related Concept Videos
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Analgesia and Pain Management
